AstraZeneca-Oxford Covid-19 vaccine trial to resume

By - Integrated Care Journal

AstraZeneca-Oxford University announced on Saturday that they have resumed its UK coronavirus vaccine trial following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.

The trial was paused last week due to an unexplained illness in one of its participants.

AstraZeneca spokesperson said in a statement that the company is committed to "the safety of trial participants" and the "highest standards of conduct in clinical trials".

"AstraZeneca will continue to work with health authorities across the world and be guided as to when other clinical trials can resume to provide the vaccine broadly, equitably and at no profit during this pandemic. ” 

The Health Secretary Matt Hancock commented the news on Twitter saying: “Good news for everyone the Oxford vaccine trials are back up and running. This pause shows we will always put safety first. We will back our scientists to deliver an effective vaccine as soon as safely possible. ”

Experts say that pauses in clinical trials are common, and with a testing pool of 30,000 people, unexplained illnesses are somewhat likely to occur - but trials must still be placed on hold in order to ensure safety.

#ACJ #coronavirus #PPP